{"id":485,"date":"2014-12-09T15:21:17","date_gmt":"2014-12-09T15:21:17","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=485"},"modified":"2017-08-21T12:08:31","modified_gmt":"2017-08-21T12:08:31","slug":"primary-care-corner-with-geoffrey-modest-md-h-pylori-treatment-antibiotic-guided-therapy","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2014\/12\/09\/primary-care-corner-with-geoffrey-modest-md-h-pylori-treatment-antibiotic-guided-therapy\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: H. Pylori Treatment Antibiotic-Guided Therapy"},"content":{"rendered":"

By: Dr. Geoffrey Modest\u00a0<\/strong><\/p>\n

In many areas, there is increasing H. Pylori resistance to several antibiotics, including clarithromycin, with decreasing H Pylori\u00a0eradication rates over time.\u00a0A recent Korean study assessed the utility of selecting\u00a0antimicrobial therapy based on antibiotic susceptibility vs standard clarithromycin-based triple therapy (see\u00a0doi: 10.1038\/ajg.2014.222<\/strong>). This issue is important because H pylori is so common, affecting about 50% of the global population (and in our experience, 80-90% of people from high risk countries), is an important risk factor\u00a0for noncardiac gastric cancer, and there are significant data that H. Pylori elimination reduces the incidence of stomach cancers.\u00a0in this study\u00a0112 patients with H. Pylori and\u00a0gastric epithelial neoplasia (adenoma and adenocarcinoma)\u00a0\u00a0were randomized to a 7 day course of a proton pump inhibitor (PPI) such as pantoprazole 40mg bid, amoxacillin 1 g bid,\u00a0 and clarithromycin 500mg bid (PAC)\u00a0or, if randomized to the pretreatment antimicrobial susceptibility wing, to that regimen if sensitive to clarithromycin but substituting methronidazole 500 mg bid if resistant (PAM) or substituting levofloxacin 400mg daily (PAL)\u00a0if resistant to both clarithromycin and metronidazole.<\/p>\n

\"OLYMPUS<\/p>\n

Results:<\/p>\n

–Mean age 62, 70% male, 50% with early gastric cancer<\/p>\n

–Medication adherence was 98% in both the\u00a0clarithromycin-based triple therapy (PAC)\u00a0and the\u00a0antimicrobial susceptibility-guided therapy<\/p>\n

–Resistance pattern: 25% to\u00a0clarithromycin, 46% to metronidazole, 37%\u00a0to levofloxacin, 10% to amoxacillin, 3% to tetracycline<\/p>\n

–In the\u00a0antimicrobial susceptibility-guided therapy\u00a0wing, 78.9% received PAC, 10.5% PAM, and 10.5% PAL therapies (ie most still got PAC)<\/p>\n

–Intention-to-treat analysis found 94.7% eradication rate in antimicrobial susceptibility-guided therapy and 71.9% in clarithromycin-based triple therapy (PAC) — this 71.9% is not so different from other studies i’ve seen recently<\/p>\n

–In patients with clarithromycin resistance, the eradication rate with\u00a0antimicrobial susceptibility-guided therapy\u00a0was 12\/12 (100%), but was only 20% in those on\u00a0PAC<\/p>\n

–In those who failed therapy (10 patients involved), they were given\u00a0antimicrobial susceptibility-guided therapy,\u00a04 of whom got PAL and 6 got PPI bid, metronidazole 500mg tid, tetracycline 500mg qid and bismuth subcitrate 125mg qid for 7 days, with almost 100% success rates<\/p>\n

–Adverse events: 8% in each group, esp abdominal pain, nausea, vomiting, bitter taste, and diarrhea, with one patient dropping out of each group because of adverse events<\/p>\n

So, this study, done in an area where there was high levels of antibiotic resistance, confirmed pretty clearly that antibiotic resistance matters in terms of eradication of H. Pylori and that with appropriate antibiotics (even for only a 7-day course), there was nearly 100% success. Unfortunately, susceptibility testing is not available here in Boston. My guess is that the pattern of resistance is pretty different here from Korea where this study was done. I would not be surprised if there were even\u00a0higher rates of metronidazole and levofloxacin resistance here (both being used a lot as monotherapy for, for example, bacterial vaginosis or urinary tract infections\/pneumonia respectively, potentially leading to H. Pylori resistance) as well as to\u00a0clarithromycin (with azithromycin used so often\u00a0for upper respiratory tract infections). I spoke with a couple of gastroenterologists here\u00a0whose\u00a0approach\u00a0was just to try\u00a0regular PAC therapy, then choose one of the alternatives if no response, specifically a quadruple therapy with bismuth. However, it seems to me that\u00a0the Maastricht IV\/Florence Consensus report\u00a0in 2012 makes more sense —\u00a0that clarithromycin based triple therapy should not be used if clarithromycin resistance rates are higher than 15-20%. This Consensus report does suggest empiric\u00a0bismuth-containing quadruple therapy as first-line empirical treatment in that case, with levofloxacin-containing triple therapy as second-line, then antimicrobial resistance testing to determine third-line, if failure of second-line (although\u00a0this Korean\u00a0study questions that approach some, given the high rates of levofloxacin resistance there).\u00a0I have been using sequential therapy with great success for many\u00a0years now. This involves a more complex regimen with the first 5 days being PPI plus amoxacillin 1 gm (both bid), then followed by PPI plus clarithromycin 500mg plus metronidazole 500mg (all bid) for another 5 days. I got this from a study comparing PAC with this therapy (though I used metronidazole instead of tinidazole, since insurance would not cover tinidazole, though that is likely better — less resistance). This study\u00a0found pretty remarkably that there was a 90% H. Pylori clearance rate in those with documented\u00a0clarithromycin-resistance, positing that since clarithromycin-resistance is from cells developing efflux channels to clarithromycin and transporting the antibiotic out of bacterial cells, but that the pretreatment with amoxacillin disturbs the bacterial cell wall and prevents this from happening,\u00a0rendering the bacteria\u00a0clarithromycin-sensitive\u00a0(see\u00a0Ann Intern Med. 2007;146:556-563<\/strong>). Subsequent studies have confirmed 90%+ cure rates with sequential therapy.<\/p>\n

What does this all mean? \u00a0It seems to me that when an H. Pylori\u00a0organism is isolated (eg, with a biopsy during endoscopy), therapy should be guided by antibiotic resistance, which should be done routinely\u00a0in the microbiology lab.\u00a0but, in primary care, we mostly treat empirically. Given that, it would be really useful to know the general antibiotic susceptibility patterns of H. Pylori to devise the optimal empirical therapy. \u00a0Sort of like treating a urinary tract infection. So, I’m\u00a0not sure why, in Boston, the mecca of the high-concentration, high-cost, high-tech medical-industrial complex, that we don’t have this really useful information….. \u00a0in its absence I will continue on my merry way with sequential therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"

H. Pylori Treatment Antibiotic-Guided Therapy […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-485","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=485"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/485\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}